SAN DIEGO--(BUSINESS WIRE)--July 5, 2006--Inovio Biomedical Corporation (AMEX:INO - News) announced today that it has exercised an existing option with RMR, LLC to license certain patented technology relating to the delivery of gene-based therapeutics into skin. The license also includes other patents involving the delivery of genes or drugs via ex vivo, intratumoral, and intramuscular electroporation. As an example of potential applications, in the area of bioterrorism, RMR is currently employing its skin electroporation technology in the pre-clinical development of an anthrax vaccine under a Department of Defense Small Business Innovation Research (SBIR) Program grant. The technology may also be useful with respect to targets such as the Lassa fever virus currently being studied by the US Army in collaboration with Inovio. The ex-vivo patents are relevant to the delivery of genes to dendritic and stem cells.
